Carbonic anhydrase enzymes Ⅱ, Ⅶ, Ⅸ and Ⅻ in colorectal carcinomas

AIM To investigate expression of four alpha-carbonic anhydrases(CAs) in colorectal carcinomas(CRC) and compare the results with patients’ survival.METHODS Colorectal carcinoma samples from 539 CRC patients and control tissues were arranged as tissue microarrays and analyzed with antibodies against C...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of gastroenterology : WJG Vol. 22; no. 36; pp. 8168 - 8177
Main Authors Viikilä, Pia, Kivelä, Antti J, Mustonen, Harri, Koskensalo, Selja, Waheed, Abdul, Sly, William S, Doisy, Edward A, Pastorek, Jaromir, Pastorekova, Silvia, Parkkila, Seppo, Haglund, Caj
Format Journal Article
LanguageEnglish
Published United States Baishideng Publishing Group Inc 28.09.2016
Subjects
Online AccessGet full text
ISSN1007-9327
2219-2840
DOI10.3748/wjg.v22.i36.8168

Cover

Loading…
Abstract AIM To investigate expression of four alpha-carbonic anhydrases(CAs) in colorectal carcinomas(CRC) and compare the results with patients’ survival.METHODS Colorectal carcinoma samples from 539 CRC patients and control tissues were arranged as tissue microarrays and analyzed with antibodies against CA Ⅱ, CA Ⅶ, CA Ⅸ, and CA Ⅻ. Intensity and extent of staining were both scored from 0 to 3 in each sample. These enzyme expression levels were then correlated to patients’ survival and clinicopathological parameters, which were tumor differentiation grade and stage, site of tumor, patients’ age, and gender. Kaplan-Meier analysis and Cox regression hazard ratio model were used to analyze survival data. RESULTS CA Ⅱ and CA Ⅻ staining intensities correlated with patients’ survival in that higher expression indicated poorer prognosis. In Cox regression analysis one unit increase in the CA Ⅱ intensity increased the hazard ratio to 1.19 fold(CI: 1.04-1.37, P = 0.009). A significant correlation was also found when comparing CA Ⅻ staining intensity with survival of CRC patients(HR = 1.18, 95%CI: 1.01-1.38, P = 0.036). The extent of CA Ⅻ immunostaining did not correlate to the patients’ survival(P = 0.242, Kaplan-Meier analysis). A significant interaction between age group and extent of the CA Ⅱ staining was found. Increased extent of CA Ⅱ had a significant hazard ratio among patients 65 years and older(1.42, 95%CI: 1.16-1.73, P = 0.0006). No correlations were found between CA Ⅶ(intensity P = 0.566, extent P = 0.495, Kaplan-Meier analysis), or CA Ⅸ(intensity P = 0.879, extent P = 0.315, KaplanMeier analysis) immunostaining results and survival, or the other parameters. CONCLUSION The present findings indicate that CA Ⅱ and CA Ⅻ could be useful in predicting survival in CRC.
AbstractList To investigate expression of four alpha-carbonic anhydrases (CAs) in colorectal carcinomas (CRC) and compare the results with patients' survival. Colorectal carcinoma samples from 539 CRC patients and control tissues were arranged as tissue microarrays and analyzed with antibodies against CA II, CA VII, CA IX, and CA XII. Intensity and extent of staining were both scored from 0 to 3 in each sample. These enzyme expression levels were then correlated to patients' survival and clinicopathological parameters, which were tumor differentiation grade and stage, site of tumor, patients' age, and gender. Kaplan-Meier analysis and Cox regression hazard ratio model were used to analyze survival data. CA II and CA XII staining intensities correlated with patients' survival in that higher expression indicated poorer prognosis. In Cox regression analysis one unit increase in the CA II intensity increased the hazard ratio to 1.19 fold (CI: 1.04-1.37, P = 0.009). A significant correlation was also found when comparing CA XII staining intensity with survival of CRC patients (HR = 1.18, 95%CI: 1.01-1.38, P = 0.036). The extent of CA XII immunostaining did not correlate to the patients' survival (P = 0.242, Kaplan-Meier analysis). A significant interaction between age group and extent of the CA II staining was found. Increased extent of CA II had a significant hazard ratio among patients 65 years and older (1.42, 95%CI: 1.16-1.73, P = 0.0006). No correlations were found between CA VII (intensity P = 0.566, extent P = 0.495, Kaplan-Meier analysis), or CA IX (intensity P = 0.879, extent P = 0.315, Kaplan-Meier analysis) immunostaining results and survival, or the other parameters. The present findings indicate that CA II and CA XII could be useful in predicting survival in CRC.
AIM To investigate expression of four alpha-carbonic anhydrases(CAs) in colorectal carcinomas(CRC) and compare the results with patients’ survival.METHODS Colorectal carcinoma samples from 539 CRC patients and control tissues were arranged as tissue microarrays and analyzed with antibodies against CA Ⅱ, CA Ⅶ, CA Ⅸ, and CA Ⅻ. Intensity and extent of staining were both scored from 0 to 3 in each sample. These enzyme expression levels were then correlated to patients’ survival and clinicopathological parameters, which were tumor differentiation grade and stage, site of tumor, patients’ age, and gender. Kaplan-Meier analysis and Cox regression hazard ratio model were used to analyze survival data. RESULTS CA Ⅱ and CA Ⅻ staining intensities correlated with patients’ survival in that higher expression indicated poorer prognosis. In Cox regression analysis one unit increase in the CA Ⅱ intensity increased the hazard ratio to 1.19 fold(CI: 1.04-1.37, P = 0.009). A significant correlation was also found when comparing CA Ⅻ staining intensity with survival of CRC patients(HR = 1.18, 95%CI: 1.01-1.38, P = 0.036). The extent of CA Ⅻ immunostaining did not correlate to the patients’ survival(P = 0.242, Kaplan-Meier analysis). A significant interaction between age group and extent of the CA Ⅱ staining was found. Increased extent of CA Ⅱ had a significant hazard ratio among patients 65 years and older(1.42, 95%CI: 1.16-1.73, P = 0.0006). No correlations were found between CA Ⅶ(intensity P = 0.566, extent P = 0.495, Kaplan-Meier analysis), or CA Ⅸ(intensity P = 0.879, extent P = 0.315, KaplanMeier analysis) immunostaining results and survival, or the other parameters. CONCLUSION The present findings indicate that CA Ⅱ and CA Ⅻ could be useful in predicting survival in CRC.
AIMTo investigate expression of four alpha-carbonic anhydrases (CAs) in colorectal carcinomas (CRC) and compare the results with patients' survival.METHODSColorectal carcinoma samples from 539 CRC patients and control tissues were arranged as tissue microarrays and analyzed with antibodies against CA II, CA VII, CA IX, and CA XII. Intensity and extent of staining were both scored from 0 to 3 in each sample. These enzyme expression levels were then correlated to patients' survival and clinicopathological parameters, which were tumor differentiation grade and stage, site of tumor, patients' age, and gender. Kaplan-Meier analysis and Cox regression hazard ratio model were used to analyze survival data.RESULTSCA II and CA XII staining intensities correlated with patients' survival in that higher expression indicated poorer prognosis. In Cox regression analysis one unit increase in the CA II intensity increased the hazard ratio to 1.19 fold (CI: 1.04-1.37, P = 0.009). A significant correlation was also found when comparing CA XII staining intensity with survival of CRC patients (HR = 1.18, 95%CI: 1.01-1.38, P = 0.036). The extent of CA XII immunostaining did not correlate to the patients' survival (P = 0.242, Kaplan-Meier analysis). A significant interaction between age group and extent of the CA II staining was found. Increased extent of CA II had a significant hazard ratio among patients 65 years and older (1.42, 95%CI: 1.16-1.73, P = 0.0006). No correlations were found between CA VII (intensity P = 0.566, extent P = 0.495, Kaplan-Meier analysis), or CA IX (intensity P = 0.879, extent P = 0.315, Kaplan-Meier analysis) immunostaining results and survival, or the other parameters.CONCLUSIONThe present findings indicate that CA II and CA XII could be useful in predicting survival in CRC.
Author Pia Viikil? Antti J Kivel? Harri Mustonen Selja Koskensalo Abdul Waheed William S Sly Jaromir Pastorek Silvia Pastorekova Seppo Parkkila Caj Haglund
AuthorAffiliation School of Medicine, University of Tampere and Fimlab Ltd, Tampere University Hospital;Department of Surgery, University of Helsinki and Helsinki University Hospital;Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine;Centre of Molecular Medicine, Institute of Virology, Slovak Academy of Sciences;Research Programs Unit, Translational Cancer Biology, University of Helsinki
Author_xml – sequence: 1
  givenname: Pia
  surname: Viikilä
  fullname: Viikilä, Pia
– sequence: 2
  givenname: Antti J
  surname: Kivelä
  fullname: Kivelä, Antti J
– sequence: 3
  givenname: Harri
  surname: Mustonen
  fullname: Mustonen, Harri
– sequence: 4
  givenname: Selja
  surname: Koskensalo
  fullname: Koskensalo, Selja
– sequence: 5
  givenname: Abdul
  surname: Waheed
  fullname: Waheed, Abdul
– sequence: 6
  givenname: William S
  surname: Sly
  fullname: Sly, William S
– sequence: 7
  givenname: Edward A
  surname: Doisy
  fullname: Doisy, Edward A
– sequence: 8
  givenname: Jaromir
  surname: Pastorek
  fullname: Pastorek, Jaromir
– sequence: 9
  givenname: Silvia
  surname: Pastorekova
  fullname: Pastorekova, Silvia
– sequence: 10
  givenname: Seppo
  surname: Parkkila
  fullname: Parkkila, Seppo
– sequence: 11
  givenname: Caj
  surname: Haglund
  fullname: Haglund, Caj
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27688658$$D View this record in MEDLINE/PubMed
BookMark eNp9UTtvFDEQtlAQuQR6KrQlBXvxc203SOjEI1KkNKS2vN7ZO0e7dmLvJTp6fggNQuJf8UvwkksEKZhiZqT5HtJ8R-ggxAAIvSR4ySRXJ7eX6-UNpUvPmqUijXqCFpQSXVPF8QFaEIxlrRmVh-go50uMKWOCPkOHVDZKNUIt0OnKpjYG7yobNrsu2QwVhC-7EXL16-u3N6V9n9uPcu_K_Fn5ULk4xARuskPlbHI-xNHm5-hpb4cML_bzGF18eP959ak-O_94unp3VjvO8VT3musWOgaE9a1qlOxbbB1njbWqhZ4rJlvegtSt0xJT7BrVdSA5iB4DU5wdo7d3ulfbdoTOQZiSHcxV8qNNOxOtN_9egt-YdbwxAjOJlSgCr_cCKV5vIU9m9NnBMNgAcZsNUVRQwjljBfrqb68Hk_v_FUBzB3Ap5pygN85PdvJxtvaDIdjMQZkSlClBmRKUmYMqRPyIeK_9HwrbUzYxrK99WD9wNFZzaYG54lpwQQT_s2H2G5wlqzk
CitedBy_id crossref_primary_10_1016_j_prp_2019_01_012
crossref_primary_10_1038_srep41191
crossref_primary_10_1080_14756366_2022_2085694
crossref_primary_10_1111_apm_12894
crossref_primary_10_1111_jbg_12541
crossref_primary_10_3389_fcell_2020_595969
crossref_primary_10_3389_fphar_2022_969422
crossref_primary_10_1016_j_semcancer_2022_01_001
crossref_primary_10_12998_wjcc_v9_i18_4520
crossref_primary_10_1186_s12866_023_02991_x
crossref_primary_10_15252_embr_202050145
crossref_primary_10_1007_s00428_018_2424_z
crossref_primary_10_1038_s41598_021_88133_7
crossref_primary_10_2217_bmm_2022_0071
crossref_primary_10_3892_ol_2019_10437
crossref_primary_10_1369_00221554211050133
crossref_primary_10_1016_j_bioorg_2018_08_005
crossref_primary_10_1016_j_intimp_2021_107830
crossref_primary_10_1002_open_202100042
crossref_primary_10_3390_cells13161311
crossref_primary_10_1186_s12864_023_09672_z
crossref_primary_10_3892_mmr_2020_11047
crossref_primary_10_1038_s41598_024_76083_9
crossref_primary_10_1186_s12957_018_1432_4
crossref_primary_10_1007_s10620_021_06985_5
crossref_primary_10_1111_pin_12949
crossref_primary_10_3390_cimb46110774
crossref_primary_10_1080_13543776_2023_2245971
crossref_primary_10_1021_acs_analchem_3c04099
crossref_primary_10_3389_fonc_2022_871568
crossref_primary_10_1016_j_ejpb_2021_08_004
crossref_primary_10_1016_j_foodres_2023_113739
crossref_primary_10_1007_s13577_024_01125_3
crossref_primary_10_1111_jcmm_17027
crossref_primary_10_3390_ph16020188
crossref_primary_10_3390_ijms24032581
crossref_primary_10_1002_cam4_5562
crossref_primary_10_1016_j_gpb_2020_09_005
crossref_primary_10_1016_j_stem_2024_10_007
crossref_primary_10_1016_j_apradiso_2017_12_013
crossref_primary_10_1002_aoc_7882
crossref_primary_10_1142_S0192415X23500246
crossref_primary_10_1016_j_jcou_2020_101305
crossref_primary_10_1021_acs_jmedchem_3c01424
crossref_primary_10_3892_ol_2019_10242
Cites_doi 10.1053/gast.1997.v112.pm9024293
10.1016/S0002-9440(10)65569-1
10.1158/1055-9965.EPI-07-0080
10.1200/JCO.2001.19.16.3660
10.1016/j.biochi.2010.05.008
10.3748/wjg.v11.i2.155
10.1136/bmj.321.7267.1004
10.1200/JCO.2005.00.471
10.1007/BF00268018
10.1038/nrc3579
10.1073/pnas.95.21.12596
10.1093/molehr/6.1.68
10.1016/j.cgh.2012.07.004
10.1136/gut.2003.036848
10.4236/health.2011.31002
10.3390/cancers3022767
10.2174/156802607780636690
10.1023/A:1011910931210
10.1136/bmj.321.7265.886
10.1038/nrd3554
10.1158/1055-9965.EPI-10-0437
10.1523/JNEUROSCI.5176-03.2004
10.4049/jimmunol.133.4.1710
10.1186/1471-2407-5-41
10.1038/nrc1478
10.1136/gut.35.5.646
10.1215/15228517-2007-001
10.1073/pnas.95.13.7608
10.1016/S0002-9440(10)64762-1
10.1038/modpathol.2009.189
10.1016/S0065-2423(06)42005-9
10.3748/wjg.v11.i17.2616
10.1158/0008-5472.CAN-03-2224
10.1136/bmj.321.7266.943
10.1002/med.10025
ContentType Journal Article
Copyright The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. 2016
Copyright_xml – notice: The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. 2016
DBID 2RA
92L
CQIGP
~WA
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.3748/wjg.v22.i36.8168
DatabaseName 中文科技期刊数据库
中文科技期刊数据库-CALIS站点
中文科技期刊数据库-7.0平台
中文科技期刊数据库- 镜像站点
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
DocumentTitleAlternate Carbonic anhydrase enzymes Ⅱ, Ⅶ, Ⅸ and Ⅻ in colorectal carcinomas
EISSN 2219-2840
EndPage 8177
ExternalDocumentID PMC5037085
27688658
10_3748_wjg_v22_i36_8168
90888889504849545154484950
Genre Journal Article
GroupedDBID ---
123
29R
2B.
2C~
2RA
2WC
36B
53G
5VR
8WL
92F
92I
92L
93N
93R
AAKDD
ACGFO
AENEX
AFUIB
ALMA_UNASSIGNED_HOLDINGS
CCEZO
CHBEP
CIEJG
CQIGP
CS3
CW9
DIK
DU5
E3Z
EBS
EJD
EMB
F5P
FA0
FRP
GX1
HYE
M~E
OK1
P2P
RNS
RPM
SV3
TCJ
TGQ
TR2
WFFXF
XSB
~WA
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c440t-f949bed3e13fb8687fb0ac436aa8bef4837b4be79bc97020c68dde74e5f0e3843
ISSN 1007-9327
IngestDate Thu Aug 21 18:14:56 EDT 2025
Fri Jul 11 02:20:47 EDT 2025
Thu Apr 03 07:05:55 EDT 2025
Tue Jul 01 02:11:28 EDT 2025
Thu Apr 24 22:58:56 EDT 2025
Wed Feb 14 10:15:14 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 36
Keywords Immunohistochemistry
Biomarker
Prognosis
Carbonic anhydrase
Survival
Colorectal cancer
Language English
License This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c440t-f949bed3e13fb8687fb0ac436aa8bef4837b4be79bc97020c68dde74e5f0e3843
Notes Pia Viikil?;Antti J Kivel?;Harri Mustonen;Selja Koskensalo;Abdul Waheed;William S Sly;Jaromir Pastorek;Silvia Pastorekova;Seppo Parkkila;Caj Haglund;School of Medicine, University of Tampere and Fimlab Ltd, Tampere University Hospital;Department of Surgery, University of Helsinki and Helsinki University Hospital;Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine;Centre of Molecular Medicine, Institute of Virology, Slovak Academy of Sciences;Research Programs Unit, Translational Cancer Biology, University of Helsinki
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Correspondence to: Pia Viikilä, MD, School of Medicine, University of Tampere and Fimlab Ltd, Tampere University Hospital, Medisiinarinkatu 3, 33014 Tampere, Finland. viikila.pia.m@student.uta.fi
Author contributions: Viikilä P, Parkkila S, Kivelä AJ and Haglund C participated in the design of the study; Clinical and survival data were collected by Koskensalo S and Haglund C; Haglund C collected samples of this study and constructed tissue microarrays; Immunohistochemical staining and light microscopy was performed by Viikilä P; Waheed A, Sly WS, Pastorek J, Pastorekova S and Parkkila S produced and characterized the primary antibodies; Statistical analysis was done by Mustonen H; Viikilä P drafted the first version of the manuscript; all authors were involved in the writing process, read, and approved the final manuscript.
Telephone: +358-408-275235
Supported by the Sigrid Jusélius Foundation, the Academy of Finland, the Medical Research Funds of Tampere University Hospital and Helsinki University Hospital, and Jane and Aatos Erkko Foundation.
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC5037085
PMID 27688658
PQID 1825214433
PQPubID 23479
PageCount 10
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5037085
proquest_miscellaneous_1825214433
pubmed_primary_27688658
crossref_citationtrail_10_3748_wjg_v22_i36_8168
crossref_primary_10_3748_wjg_v22_i36_8168
chongqing_primary_90888889504849545154484950
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2016-09-28
PublicationDateYYYYMMDD 2016-09-28
PublicationDate_xml – month: 09
  year: 2016
  text: 2016-09-28
  day: 28
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle World journal of gastroenterology : WJG
PublicationTitleAlternate World Journal of Gastroenterology
PublicationYear 2016
Publisher Baishideng Publishing Group Inc
Publisher_xml – name: Baishideng Publishing Group Inc
References ref13
ref35
ref12
ref34
ref15
ref14
ref36
ref31
ref30
ref11
ref33
ref10
ref32
ref2
ref1
ref17
ref16
ref19
ref18
ref24
ref23
ref26
ref25
ref20
ref22
ref21
ref28
ref27
ref29
ref8
ref7
ref9
ref4
ref3
ref6
ref5
20647400 - Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):1893-907
8468192 - Histochemistry. 1993 Jan;99(1):37-41
11039973 - BMJ. 2000 Oct 21;321(7267):1004-6
16172461 - J Clin Oncol. 2005 Oct 20;23(30):7518-28
10666387 - Am J Pathol. 2000 Feb;156(2):577-84
15836783 - BMC Cancer. 2005 Apr 18;5:41
9636197 - Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7608-13
17435181 - Neuro Oncol. 2007 Jul;9(3):308-13
15028762 - J Neurosci. 2004 Mar 17;24(11):2699-707
23969692 - Nat Rev Cancer. 2013 Sep;13(9):611-23
6206131 - J Immunol. 1984 Oct;133(4):1710-5
15633208 - World J Gastroenterol. 2005 Jan 14;11(2):155-63
15516961 - Nat Rev Cancer. 2004 Nov;4(11):891-9
17504127 - Curr Top Med Chem. 2007;7(9):825-33
9665489 - Am J Pathol. 1998 Jul;153(1):279-85
11030689 - BMJ. 2000 Oct 14;321(7266):943-6
15710986 - Gut. 2005 Mar;54(3):374-84
11021873 - BMJ. 2000 Oct 7;321(7265):886-9
10611263 - Mol Hum Reprod. 2000 Jan;6(1):68-74
15849821 - World J Gastroenterol. 2005 May 7;11(17 ):2616-25
9770531 - Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12596-601
20493921 - Biochimie. 2010 Aug;92(8):1072-80
24212832 - Cancers (Basel). 2011 Jun 23;3(2):2767-810
20081808 - Mod Pathol. 2010 May;23(5):743-50
8200558 - Gut. 1994 May;35(5):646-50
9024293 - Gastroenterology. 1997 Feb;112(2):398-408
22835574 - Clin Gastroenterol Hepatol. 2012 Dec;10(12):1395-1401.e2
11504747 - J Clin Oncol. 2001 Aug 15;19(16):3660-8
11691824 - Cancer Res. 2001 Nov 1;61(21):7992-8
21921921 - Nat Rev Drug Discov. 2011 Sep 16;10(10):767-77
12500287 - Med Res Rev. 2003 Mar;23(2):146-89
15342400 - Cancer Res. 2004 Sep 1;64(17 ):6160-5
11680594 - Dig Dis Sci. 2001 Oct;46(10 ):2179-86
17131627 - Adv Clin Chem. 2006;42:167-216
17855694 - Cancer Epidemiol Biomarkers Prev. 2007 Sep;16(9):1760-6
References_xml – ident: ref24
  doi: 10.1053/gast.1997.v112.pm9024293
– ident: ref18
  doi: 10.1016/S0002-9440(10)65569-1
– ident: ref35
  doi: 10.1158/1055-9965.EPI-07-0080
– ident: ref27
  doi: 10.1200/JCO.2001.19.16.3660
– ident: ref23
  doi: 10.1016/j.biochi.2010.05.008
– ident: ref9
  doi: 10.3748/wjg.v11.i2.155
– ident: ref2
  doi: 10.1136/bmj.321.7267.1004
– ident: ref6
  doi: 10.1200/JCO.2005.00.471
– ident: ref22
  doi: 10.1007/BF00268018
– ident: ref12
  doi: 10.1038/nrc3579
– ident: ref21
  doi: 10.1073/pnas.95.21.12596
– ident: ref25
  doi: 10.1093/molehr/6.1.68
– ident: ref36
  doi: 10.1016/j.cgh.2012.07.004
– ident: ref34
  doi: 10.1136/gut.2003.036848
– ident: ref17
  doi: 10.4236/health.2011.31002
– ident: ref5
  doi: 10.3390/cancers3022767
– ident: ref10
  doi: 10.2174/156802607780636690
– ident: ref32
  doi: 10.1023/A:1011910931210
– ident: ref3
  doi: 10.1136/bmj.321.7265.886
– ident: ref13
  doi: 10.1038/nrd3554
– ident: ref1
  doi: 10.1158/1055-9965.EPI-10-0437
– ident: ref16
  doi: 10.1523/JNEUROSCI.5176-03.2004
– ident: ref7
  doi: 10.4049/jimmunol.133.4.1710
– ident: ref28
– ident: ref33
  doi: 10.1186/1471-2407-5-41
– ident: ref11
  doi: 10.1038/nrc1478
– ident: ref14
  doi: 10.1136/gut.35.5.646
– ident: ref29
  doi: 10.1215/15228517-2007-001
– ident: ref31
  doi: 10.1073/pnas.95.13.7608
– ident: ref20
  doi: 10.1016/S0002-9440(10)64762-1
– ident: ref15
  doi: 10.1038/modpathol.2009.189
– ident: ref26
  doi: 10.1016/S0065-2423(06)42005-9
– ident: ref19
  doi: 10.3748/wjg.v11.i17.2616
– ident: ref30
  doi: 10.1158/0008-5472.CAN-03-2224
– ident: ref4
  doi: 10.1136/bmj.321.7266.943
– ident: ref8
  doi: 10.1002/med.10025
– reference: 11691824 - Cancer Res. 2001 Nov 1;61(21):7992-8
– reference: 8200558 - Gut. 1994 May;35(5):646-50
– reference: 15849821 - World J Gastroenterol. 2005 May 7;11(17 ):2616-25
– reference: 15028762 - J Neurosci. 2004 Mar 17;24(11):2699-707
– reference: 9024293 - Gastroenterology. 1997 Feb;112(2):398-408
– reference: 10611263 - Mol Hum Reprod. 2000 Jan;6(1):68-74
– reference: 8468192 - Histochemistry. 1993 Jan;99(1):37-41
– reference: 15516961 - Nat Rev Cancer. 2004 Nov;4(11):891-9
– reference: 11030689 - BMJ. 2000 Oct 14;321(7266):943-6
– reference: 20081808 - Mod Pathol. 2010 May;23(5):743-50
– reference: 17504127 - Curr Top Med Chem. 2007;7(9):825-33
– reference: 15836783 - BMC Cancer. 2005 Apr 18;5:41
– reference: 20647400 - Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):1893-907
– reference: 15633208 - World J Gastroenterol. 2005 Jan 14;11(2):155-63
– reference: 9665489 - Am J Pathol. 1998 Jul;153(1):279-85
– reference: 12500287 - Med Res Rev. 2003 Mar;23(2):146-89
– reference: 11680594 - Dig Dis Sci. 2001 Oct;46(10 ):2179-86
– reference: 9636197 - Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7608-13
– reference: 15342400 - Cancer Res. 2004 Sep 1;64(17 ):6160-5
– reference: 22835574 - Clin Gastroenterol Hepatol. 2012 Dec;10(12):1395-1401.e2
– reference: 23969692 - Nat Rev Cancer. 2013 Sep;13(9):611-23
– reference: 17131627 - Adv Clin Chem. 2006;42:167-216
– reference: 11039973 - BMJ. 2000 Oct 21;321(7267):1004-6
– reference: 10666387 - Am J Pathol. 2000 Feb;156(2):577-84
– reference: 20493921 - Biochimie. 2010 Aug;92(8):1072-80
– reference: 21921921 - Nat Rev Drug Discov. 2011 Sep 16;10(10):767-77
– reference: 17855694 - Cancer Epidemiol Biomarkers Prev. 2007 Sep;16(9):1760-6
– reference: 24212832 - Cancers (Basel). 2011 Jun 23;3(2):2767-810
– reference: 15710986 - Gut. 2005 Mar;54(3):374-84
– reference: 6206131 - J Immunol. 1984 Oct;133(4):1710-5
– reference: 16172461 - J Clin Oncol. 2005 Oct 20;23(30):7518-28
– reference: 9770531 - Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12596-601
– reference: 11504747 - J Clin Oncol. 2001 Aug 15;19(16):3660-8
– reference: 11021873 - BMJ. 2000 Oct 7;321(7265):886-9
– reference: 17435181 - Neuro Oncol. 2007 Jul;9(3):308-13
SSID ssj0023352
Score 2.4174428
Snippet AIM To investigate expression of four alpha-carbonic anhydrases(CAs) in colorectal carcinomas(CRC) and compare the results with patients’ survival.METHODS...
To investigate expression of four alpha-carbonic anhydrases (CAs) in colorectal carcinomas (CRC) and compare the results with patients' survival. Colorectal...
AIMTo investigate expression of four alpha-carbonic anhydrases (CAs) in colorectal carcinomas (CRC) and compare the results with patients'...
SourceID pubmedcentral
proquest
pubmed
crossref
chongqing
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 8168
SubjectTerms Aged
anhydrase;Colorectal
Antigens, Neoplasm - metabolism
Basic Study
Biomarker;Carbonic
Biomarkers, Tumor - metabolism
cancer;Immunohistochemistry;Prognosis;Survival
Carbonic Anhydrase II - metabolism
Carbonic Anhydrase IX - metabolism
Carbonic Anhydrases - metabolism
Colorectal Neoplasms - enzymology
Colorectal Neoplasms - mortality
Female
Gene Expression Regulation, Neoplastic
Humans
Immunohistochemistry
Kaplan-Meier Estimate
Male
Middle Aged
Prognosis
Proportional Hazards Models
Regression Analysis
Tissue Array Analysis
Treatment Outcome
Title Carbonic anhydrase enzymes Ⅱ, Ⅶ, Ⅸ and Ⅻ in colorectal carcinomas
URI http://lib.cqvip.com/qk/84123X/201636/90888889504849545154484950.html
https://www.ncbi.nlm.nih.gov/pubmed/27688658
https://www.proquest.com/docview/1825214433
https://pubmed.ncbi.nlm.nih.gov/PMC5037085
Volume 22
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLa28bIXBOJWbgoSfkBeuyTOxXlsu1Zj0xDSNthbZCfOmi0ko2uHtnd-CC8IiX_FL-GcNEnbwSRGVbnxPfJ3enyOfXxMyGs_gmkziXhbxY7Zdnzut5UQCagqXhzpJHZ1hIri3jtv-9DZOXKPVlbXF6yWphPVia7-eq7kf1CFNMAVT8neAtmmUUiAZ8AXQkAYwn_CuC_HqrzBRuajy3gMExLT-dVl6X8JjRhc2rVwDOuItxgR5b5BHeux0iAdtHfggOgzBO8YyhvjoUp8pQOH9gQNPDrwaeBS0acDQQXHLz7YtGuWWT42OoB2t7DXgUeDLcyFlN4QcwdD2uvToFvW6tGeVZbxqPCxugioaExs36eSfUjT0zSjfIjODiYp22G7wKXLhG05Hqdsb4pCrEbel51Itlucn4J-LrOCdVU8zdhHOYJpuvZBwfbZfnbJduS4-JSOQYpGE1F9yvbT7AJ6q-PFhYT2zs4KhmfD4QUk68sT6PE4m-bx4nqJ5aFxh73I4nFxFqTW2TSvyzQb-DYUmjmOqiieL_J1vJ1kUUawZnfPXJ9_0JcPEM2Xk-POhW13Uu515jWXvHqjeRl8Ahc4KOiojotekfDJXCV3bFB57HrlqVo8wLNx5c599fazLXfscPN6d-gmZFTkx59B-FkWt_7Qoa6bAi_IVgf3yN1KKTK6Mwq_T1Z0_oC8ranbaKjbqKjb-PX12wYE3zH4Afkx_P400tyYU7Axp-CH5HA4OOhvt6uLP9qR45iTdhI4gdIx1xZPlPCEnyhTRg73pBRKJ3gJgnKU9gMVBT7oO5EnYJb2He0mpubC4Y_IWg5E94QYllbCkj6XyowcV4sg0bYplRXb2rR1bLfIRjNW4dnMwUt4MzgtslkPZxhVTvTxLpcsBGUawQgBjBDACAGMEMFokTdNjbr9m8u-qhEKgcvj1p3MdTE9Dy1hu-jckPMWeTxDrGnN9j0hQJFoEX8Jy6YAepBfzsnTUelJ3jW5DzrX09sNwjOyPv9jPSdrk_FUvwDRfKJeljT7G1AF0XA
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Carbonic+anhydrase+enzymes+%E2%85%A1%2C+%E2%85%A6%2C+%E2%85%A8+and+%E2%85%AB+in+colorectal+carcinomas&rft.jtitle=%E4%B8%96%E7%95%8C%E8%83%83%E8%82%A0%E7%97%85%E5%AD%A6%E6%9D%82%E5%BF%97%EF%BC%9A%E8%8B%B1%E6%96%87%E7%89%88&rft.au=Pia+Viikil%3F+Antti+J+Kivel%3F+Harri+Mustonen+Selja+Koskensalo+Abdul+Waheed+William+S+Sly+Jaromir+Pastorek+Silvia+Pastorekova+Seppo+Parkkila+Caj+Haglund&rft.date=2016-09-28&rft.issn=1007-9327&rft.eissn=2219-2840&rft.issue=36&rft.spage=8168&rft.epage=8177&rft_id=info:doi/10.3748%2Fwjg.v22.i36.8168&rft.externalDocID=90888889504849545154484950
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F84123X%2F84123X.jpg